Bio Insight Bio Reports
When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...
June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibod...
May 20, 2026 | News
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with Bacillus Calmette-Guérin (BCG)-unresponsive n...
May 19, 2026 | News
Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial ...
May 19, 2026 | News
Akeso, Inc. announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will ...
May 18, 2026 | News
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...
May 13, 2026 | News
Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world's most powerful supercomputers to simu...
May 06, 2026 | News
AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent...
May 01, 2026 | News
High Impact Session presented at Heart Rhythm Society's Congress in Chicago First time showing results of new Less Invasive approach Improvement in Lef...
April 27, 2026 | News
Chromatography in Bioprocessing For pilot and commercial purification of monoclonal antibodies and recombinant proteins, chromatography remains the centra...
April 24, 2026 | Analysis
Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presen...
April 24, 2026 | News
NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed ac...
April 21, 2026 | News
First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...
April 21, 2026 | News
SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively chang...
April 20, 2026 | News
Most Read
Bio Jobs
News